SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Icagen (Nasdaq: ICGN) $3.41. Today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed. "We are pleased with the FDA's action and will shortly be determining the next steps in the clinical development of our epilepsy drug candidate, ICA-105665," noted President and CEO P. Kay Wagoner.
What They Do: Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets.
EDAP TMS SA (Nasdaq: EDAP) $3.89. Today announced it has been granted a special temporary reimbursement for Ablatherm-HIFU for the treatment of localized prostate cancer by the French National Authority for Health ("HAS"). The grant follows a comprehensive review of Ablatherm-HIFU clinical results. This step by HAS reflects a new reimbursement process dedicated to innovative therapies, which allows Ablatherm-HIFU technology to be granted temporary reimbursement while setting up a dedicated treatment registry for the next five years.
Marc Oczachowski, Chief Executive Officer of EDAP TMS, commented, "This temporary reimbursement is a major milestone towards establishing definitive reimbursement in France for our HIFU treatment for localized prostate cancer. It clearly validates Ablatherm-HIFU's growth potential in France. HAS estimates the potential number of patients to be treated annually by our technology to be approximately 10,000 primary care patients and 800 radiotherapy failure patients. We see this potential as a significant expansion opportunity compared to a total of 800 patients treated last year in France without reimbursement."
What They Do: EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer.
iGo, Inc. (Nasdaq: IGOI) $3.45. Today announced it jhas been awarded Great Britain Patent Nos. GB2469003 and GB2471030, the first two patents the company has been awarded in the United Kingdom related to its unique, power-saving iGo Green technology.
The first two Great Britain Patents relate specifically to the use of iGo Green technology as a primary side controller in a laptop power adapter. A power adapter using iGo Green technology recognizes when a device does not require power and automatically shuts itself off, thus reducing the power draw to ultra-low levels. When the device needs power again, the power adapter turns itself on, automatically.
What They Do: iGo, Inc. offers a full line of innovative accessories for almost every mobile electronic device on the market.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
